Advertisement

Normalization of Affymetrix miRNA Microarrays for the Analysis of Cancer Samples

  • Di Wu
  • Michael P. GantierEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1375)

Abstract

microRNA (miRNA) microarray normalization is a critical step for the identification of truly differentially expressed miRNAs. This is particularly important when dealing with cancer samples that have a global miRNA decrease. In this chapter, we provide a simple step-by-step procedure that can be used to normalize Affymetrix miRNA microarrays, relying on robust normal-exponential background correction with cyclic loess normalization.

Keywords

microRNA miRNA microarray Normalization Cancer samples Affymetrix 

Notes

Acknowledgments

The authors thank Frances Cribbin for her help with the redaction of this review. The authors are supported by funding from the Australian NHMRC (1022144 and 1062683 to MPG and 1036541 to DW) and the Victorian Government’s Operational Infrastructure Support Program.

References

  1. 1.
    Melo SA, Esteller M (2011) Dysregulation of microRNAs in cancer: playing with fire. FEBS Lett 585(13):2087–2099CrossRefPubMedGoogle Scholar
  2. 2.
    Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, Kira S, Yoshida Y, Seto M (2004) Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 64(9):3087–3095CrossRefPubMedGoogle Scholar
  3. 3.
    Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM (2002) Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 99(24):15524–15529CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Melo SA, Moutinho C, Ropero S, Calin GA, Rossi S, Spizzo R, Fernandez AF, Davalos V, Villanueva A, Montoya G, Yamamoto H, Schwartz S, Esteller M (2010) A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell 18(4):303–315CrossRefPubMedGoogle Scholar
  5. 5.
    Melo SA, Ropero S, Moutinho C, Aaltonen LA, Yamamoto H, Calin GA, Rossi S, Fernandez AF, Carneiro F, Oliveira C, Ferreira B, Liu C-G, Villanueva A, Capella G, Schwartz S, Shiekhattar R, Esteller M (2009) A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet 41(3):365–370CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng J-F, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK (2008) Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 359(25):2641–2650CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR (2005) MicroRNA expression profiles classify human cancers. Nature 435(7043):834–838CrossRefPubMedGoogle Scholar
  8. 8.
    Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, Ambros VR, Israel MA (2007) Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 67(6):2456–2468CrossRefPubMedGoogle Scholar
  9. 9.
    Volinia S, Calin GA, Liu C-G, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103(7):2257–2261CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu C-G, Croce CM, Harris CC (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9(3):189–198CrossRefPubMedGoogle Scholar
  11. 11.
    Kumar MS, Pester RE, Chen CY, Lane K, Chin C, Lu J, Kirsch DG, Golub TR, Jacks T (2009) Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev 23(23):2700–2704CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Karube Y, Tanaka H, Osada H, Tomida S, Tatematsu Y, Yanagisawa K, Yatabe Y, Takamizawa J, Miyoshi S, Mitsudomi T, Takahashi T (2005) Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci 96(2):111–115CrossRefPubMedGoogle Scholar
  13. 13.
    Grelier G, Voirin N, Ay A-S, Cox DG, Chabaud S, Treilleux I, Leon-Goddard S, Rimokh R, Mikaelian I, Venoux C, Puisieux A, Lasset C, Moyret-Lalle C (2009) Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype. Br J Cancer 101(4):673–683CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Wu D, Hu Y, Tong S, Williams BR, Smyth GK, Gantier MP (2013) The use of miRNA microarrays for the analysis of cancer samples with global miRNA decrease. RNA 19(7):876–888CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of StatisticsHarvard UniversityCambridgeUSA
  2. 2.Centre for Cancer ResearchMIMR-PHI Institute of Medical ResearchClaytonAustralia
  3. 3.Department of Molecular and Translational ScienceMonash UniversityClaytonAustralia

Personalised recommendations